Hamill Laura 4

What Happened

Laura Hamill, a director of Fate Therapeutics (FATE), was granted a derivative equity award on June 12, 2026: options covering 175,800 shares. The grant price reported is $0.00 (no cash paid at grant). This is an equity compensation award under the company's non-employee director policy, not an open‑market purchase or sale.

Key Details

• Transaction date: June 12, 2026; Form 4 filed June 15, 2026 (timely).
• Transaction type/code: A (Award/Grant) — derivative securities (options).
• Amount granted: 175,800 option shares; grant price shown as $0.00.
• Vesting: Options vest in 36 equal monthly installments beginning June 12, 2026, and are fully vested and exercisable on June 12, 2029, subject to continuous service (per footnote).
• Reason/plan: Grant made pursuant to the Issuer’s Amended and Restated Non-Employee Director Compensation Policy (per footnote).
• Shares owned after transaction: Not specified in the filing.

Context

This is a standard director equity grant intended as long‑term compensation and subject to multi‑year vesting; it does not indicate an immediate purchase or sale of stock. As a derivative award, the options only convert to stock if/when exercised according to the plan and vesting schedule. No judgment about Hamill’s views of the company’s prospects can be drawn solely from this routine compensation grant.